# Autism Spectrum Disorder: Early Identification and Intervention

## Introduction

Autism spectrum disorder (ASD) is a neurodevelopmental condition characterized by persistent deficits in social communication and interaction along with restricted, repetitive patterns of behavior, interests, or activities. The current prevalence in the United States is approximately 1 in 36 children (CDC, 2023), with a male-to-female ratio of approximately 4:1, though underdiagnosis in girls is increasingly recognized. Early identification, ideally before age 2, enables access to evidence-based interventions during a critical window of neuroplasticity, significantly improving long-term outcomes.

## Diagnostic Criteria (DSM-5)

### Domain A: Persistent Deficits in Social Communication and Social Interaction

Deficits in social-emotional reciprocity include reduced sharing of interests, emotions, or affect; failure of normal back-and-forth conversation; and reduced initiation of social interaction. Deficits in nonverbal communicative behaviors include poor integration of verbal and nonverbal communication, abnormal eye contact and body language, deficits in understanding and use of gestures, and reduced facial expressiveness. Deficits in developing, maintaining, and understanding relationships include difficulty adjusting behavior to social context, difficulty sharing imaginative play, difficulty making friends, and absent interest in peers.

### Domain B: Restricted, Repetitive Patterns of Behavior, Interests, or Activities (at least 2 of 4)

The four criteria include stereotyped or repetitive motor movements, use of objects, or speech (echolalia, idiosyncratic phrases, lining up toys, hand flapping); insistence on sameness, inflexible adherence to routines, and ritualized patterns with extreme distress at small changes and rigid thinking; highly restricted, fixated interests that are abnormal in intensity or focus (strong attachment to unusual objects, perseverative interests); and hyper- or hypo-reactivity to sensory input or unusual interest in sensory aspects (apparent indifference to pain or temperature, adverse response to specific sounds or textures, excessive smelling or touching, visual fascination with lights or movement).

### Severity Levels

| Severity Level | Social Communication | Restricted/Repetitive Behaviors | Functional Impact |
|---------------|---------------------|--------------------------------|-------------------|
| Level 1: Requiring support | Noticeable difficulties initiating interactions; atypical responses | Inflexibility causes interference; difficulty switching activities | Can function independently with support |
| Level 2: Requiring substantial support | Marked deficits; limited social initiation; reduced response to overtures | Restricted behaviors obvious to casual observer; distress with change | Requires substantial support; deficits apparent in multiple settings |
| Level 3: Requiring very substantial support | Severe deficits in verbal/nonverbal communication; very limited initiation | Extreme difficulty with change; markedly restricted behaviors; great distress | Requires very substantial support; significant impairment in all domains |

Level 1 ("Requiring support") involves noticeable social difficulties and inflexibility, with the ability to function independently with support. Level 2 ("Requiring substantial support") involves marked deficits in social communication with restricted behaviors that are obvious to a casual observer. Level 3 ("Requiring very substantial support") involves severe deficits in verbal and nonverbal communication, extreme difficulty with change, and markedly restricted behaviors.

## Early Signs and Red Flags

### By 12 Months

Warning signs include no babbling or gesturing (pointing, waving), no response to name, poor eye contact, and lack of shared attention (not following a point, not showing objects).

### By 16-18 Months

Concerns include no single words, no pretend play, and loss of previously acquired language or social skills (regression occurs in approximately 25-30% of ASD cases).

### By 24 Months

Red flags include no two-word meaningful phrases (not including echolalia), lack of interest in other children, and emerging repetitive behaviors such as lining up toys or spinning objects.

### At Any Age

At any age, loss of language or social skills, avoidance of eye contact, preference for solitary play, unusual sensory behaviors (covering ears, visual fixation), and lack of pointing to show interest (protodeclarative pointing) should prompt evaluation.

<image>Timeline illustration showing normal developmental milestones alongside early red flags for autism spectrum disorder at 6 months, 12 months, 18 months, and 24 months, with specific social communication and behavioral indicators highlighted at each age</image>

## Screening and Diagnostic Evaluation

### Universal Screening (AAP Recommendations)

Developmental surveillance should occur at every well-child visit. Autism-specific screening using the M-CHAT-R/F (Modified Checklist for Autism in Toddlers, Revised with Follow-up) should be performed at 18 and 24 months. This 20-item parent questionnaire takes 5 minutes to complete. A score of 0-2 indicates low risk (rescreen at next visit if under 24 months), 3-7 indicates medium risk (administer the Follow-Up Interview to reduce false positives), and 8-20 indicates high risk (refer immediately for diagnostic evaluation). Screening should occur at any age if developmental concerns arise, and rescreening at 30 months should be considered in high-risk populations such as siblings of children with ASD.

### Diagnostic Evaluation

A comprehensive developmental assessment is conducted by a multidisciplinary team including a developmental pediatrician, child psychologist, and speech-language pathologist. Gold standard diagnostic tools include the ADOS-2 (Autism Diagnostic Observation Schedule), a structured play-based assessment, and the ADI-R (Autism Diagnostic Interview-Revised), a comprehensive parent interview. Cognitive and developmental testing assesses intellectual functioning and adaptive skills. Speech-language evaluation addresses receptive and expressive language and pragmatic language. Hearing evaluation with audiologic testing rules out hearing impairment as a cause of language delay.

### Medical Workup

Genetic testing begins with chromosomal microarray (CMA) as the first-line test, with consideration of fragile X testing and whole exome sequencing for unresolved cases. An identifiable genetic etiology is found in approximately 30-40% of ASD cases, with associated conditions including Fragile X syndrome, tuberous sclerosis, Rett syndrome, 22q11.2 deletion, and PTEN mutations. EEG is indicated if there is clinical concern for seizures, as epilepsy co-occurs in 20-30% of individuals with ASD. Lead level and metabolic screening should be performed if clinically indicated. Brain MRI is not routinely recommended unless focal neurologic findings or macrocephaly with regression are present.

<image>Diagnostic pathway flowchart for autism spectrum disorder showing universal M-CHAT-R/F screening at 18 and 24 months, follow-up interview process, referral to multidisciplinary evaluation (ADOS-2, developmental testing, speech assessment), medical workup (genetic testing, audiometry), and connection to early intervention services</image>

## Co-Occurring Conditions

Intellectual disability is present in approximately 30-40% of individuals with ASD. Language disorders affect 25-30%, with some individuals being minimally verbal or nonverbal. ADHD co-occurs in 30-60% (DSM-5 now allows dual diagnosis). Anxiety disorders are present in 40-50%. Sleep disorders affect 50-80%, with melatonin as the first-line pharmacologic treatment. Epilepsy occurs in 20-30%, with bimodal peaks in early childhood and adolescence. GI symptoms including constipation, food selectivity, and GERD are common but are not caused by ASD-specific GI pathology. Feeding difficulties related to sensory-based food selectivity (texture, color) may lead to nutritional deficiencies.

## Intervention

### Early Intensive Behavioral Intervention

Applied Behavior Analysis (ABA) is the most extensively studied and supported intervention. It uses systematic teaching methods based on learning principles and is recommended at 25-40 hours per week for young children. Naturalistic Developmental Behavioral Interventions (NDBIs) combine behavioral and developmental approaches in natural settings and include the Early Start Denver Model (ESDM), JASPER, and Pivotal Response Training. Early intervention services under Part C of IDEA are federally mandated for children birth to 3 years and require only a demonstrated delay, not a diagnosis.

### Speech-Language Therapy

Therapy targets both verbal and nonverbal communication. Augmentative and alternative communication (AAC) options include picture exchange (PECS), speech-generating devices, and sign language for minimally verbal children. Importantly, AAC does not inhibit spoken language development.

### Occupational Therapy

Occupational therapy addresses sensory integration therapy for sensory processing difficulties, as well as fine motor skills, self-care skills, and handwriting.

### Educational Supports

An Individualized Education Program (IEP) under IDEA Part B serves children ages 3-21. Structured teaching environments, visual supports, and social skills training are key components. Many children benefit from inclusion with appropriate supports.

### Pharmacotherapy

No medication treats core ASD symptoms. Medications target co-occurring symptoms: risperidone (FDA-approved for ages 5 and older) and aripiprazole (FDA-approved for ages 6 and older) address irritability and aggression, though weight gain and metabolic effects must be monitored. ADHD symptoms can be treated with methylphenidate, atomoxetine, or guanfacine, though these may be less effective and less well-tolerated than in neurotypical ADHD. SSRIs may help with anxiety (limited pediatric data in ASD; start low, go slow). Melatonin has evidence supporting its efficacy and safety for sleep in ASD. SSRIs have modest evidence for repetitive behaviors.

<image>Comprehensive intervention model for autism spectrum disorder showing the multimodal approach across ages: early intervention (birth-3), preschool behavioral interventions (ABA, ESDM), school-age supports (IEP, social skills groups, speech/OT), and adolescent/adult transition planning, with pharmacotherapy options for co-occurring conditions</image>

## Clinical Pearls

All children should be screened for ASD at 18 and 24 months -- clinicians should not wait for concerns to arise, as early detection changes outcomes. Regression of previously acquired skills, especially language, warrants urgent evaluation; it occurs in about 25-30% of ASD cases and can also indicate Rett syndrome or other conditions. The spectrum is wide, and severity, strengths, and challenges vary enormously among individuals. Co-occurring conditions including ADHD, anxiety, sleep disturbance, and epilepsy are the rule rather than the exception, and clinicians should screen proactively and treat. Referral to early intervention services should occur immediately upon concern, without waiting for a formal ASD diagnosis, because early intervention eligibility is based on developmental delay, not diagnosis.

## References

1. Hyman SL, Levy SE, Myers SM, et al. Identification, Evaluation, and Management of Children with Autism Spectrum Disorder. *Pediatrics*. 2020;145(1):e20193447.
2. Maenner MJ, Warren Z, Williams AR, et al. Prevalence and Characteristics of Autism Spectrum Disorder Among Children Aged 8 Years — Autism and Developmental Disabilities Monitoring Network, 11 Sites, United States, 2020. *MMWR Surveill Summ*. 2023;72(2):1-14.
3. Dawson G, Rogers S, Munson J, et al. Randomized, Controlled Trial of an Intervention for Toddlers with Autism: The Early Start Denver Model. *Pediatrics*. 2010;125(1):e17-e23.
4. Schaefer GB, Mendelsohn NJ, Professional Practice and Guidelines Committee. Clinical Genetics Evaluation in Identifying the Etiology of Autism Spectrum Disorders: 2013 Guideline Revisions. *Genet Med*. 2013;15(5):399-407.